Accuray Stock (NASDAQ:ARAY)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.85

52W Range

$1.40 - $3.05

50D Avg

$1.91

200D Avg

$1.95

Market Cap

$188.06M

Avg Vol (3M)

$615.76K

Beta

1.40

Div Yield

-

ARAY Company Profile


Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Show More

Industry

Medical - Specialties

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

987

IPO Date

Feb 08, 2007

Website

ARAY Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Jun 23Jun 22
Service$212.39M$214.41M$357.86M
Product$234.16M$233.19M$342.00M

Fiscal year ends in Jun 24 | Currency in USD

ARAY Financial Summary


Jun 24Jun 23Jun 22
Revenue$446.55M$447.61M$429.91M
Operating Income$504.00K$2.38M$2.63M
Net Income$-15.54M$-9.28M$-5.35M
EBITDA$6.41M$2.38M$8.15M
Basic EPS$-0.16$-0.10$-0.06
Diluted EPS$-0.16$-0.10$-0.06

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25Nov 06, 24 | 10:29 PM
Q4 24Aug 14, 24 | 9:02 PM
Q3 24May 01, 24 | 9:36 PM

Peer Comparison


TickerCompany
FNAParagon 28, Inc.
ANIKAnika Therapeutics, Inc.
APYXApyx Medical Corporation
OFIXOrthofix Medical Inc.
TELATELA Bio, Inc.
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
KIDSOrthoPediatrics Corp.
CUTRCutera, Inc.
CTSOCytosorbents Corporation
AVNSAvanos Medical, Inc.
SGHTSight Sciences, Inc.
CLPTClearPoint Neuro, Inc.
BVSBioventus Inc.
AXGNAxoGen, Inc.
SIBNSI-BONE, Inc.
AORTArtivion, Inc.